Activating certain receptors in the amygdala — a treatment that runs counter to a leading theory of what causes the condition — can reverse some traits in rats.
Spectrum: Autism Research News
Elizabeth Berry-Kravis has spent decades uncovering molecular clues to fragile X syndrome and crafting trials of treatments. Her efforts are paying off.
A gene therapy for Angelman syndrome stands at the forefront of efforts to treat autism-linked conditions that stem from single genes.
Drug after drug has failed in clinical trials for fragile X syndrome. A new study provides an explanation — a decrease in the drugs’ effectiveness over time — and points to a new strategy that could circumvent this problem.
Many drugs for fragile X syndrome have failed in large clinical trials, but candidates that target new aspects of the condition may fare better.
Autism and intelligence share genetic variants, researchers grow Neanderthal mini-brains and see overlap with autism, and maternal diabetes is an autism risk factor.
Many people with fragile X syndrome show average rates of protein production, challenging a long-held assumption about the condition.
The drug mavoglurant has no effect on a brain circuit involved in social behavior in a mouse model of fragile X syndrome. That may explain its poor performance in people with the condition.